View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 21, 2022

Hinova doses first patient in Phase I castration-resistant prostate cancer trial

HP518 is highly selective for AR, a therapeutic target which has been validated for prostate cancer treatment.

Hinova Pharmaceuticals has dosed the first subject in a Phase I clinical trial of its oral therapy HP518 to treat metastatic castration-resistant prostate cancer (mCRPC).

The open-label study, which is underway in Australia, will evaluate the orally bioavailable chimeric degrader targeting androgen receptor (AR) HP518’s pharmacokinetics, safety and anti-tumour activity in mCRPC patients.

Hinova’s targeted protein degradation drug discovery platform discovered and developed the therapy.

HP518 showed high degradation activity against wild type AR and certain AR mutants in discovery and preclinical studies.

It also demonstrated antitumour activity in xenograft mouse models.

Furthermore, HP518 is intended to overcome the drug resistance of prostate cancer due to specific AR mutations.

Hinova Pharmaceuticals president and CEO Yuanwei Chen said: “The dosing of the first patient is a significant milestone in the progress of our efforts from drug discovery to the clinical study.

“We are excited about it and dedicated to bringing new treatment options to patients worldwide, and will continue to tirelessly advance our ongoing targeted protein degradation projects.”

HP518 is highly selective for AR, a therapeutic target validated for prostate cancer treatment.

The bifunctional small molecules, chimeric degraders, can promote target proteins degradation with high potency and selectivity.

Hinova focuses on the development of new treatments for cancers and metabolic diseases through targeted protein degradation technologies.

A targeted protein degradation drug discovery platform, established by Hinova, allows rapid screening of protein degradation activity and accomplish design and optimisation of Chimeric degraders.

The company also has experience in chemical manufacturing control of chimeric degrader compounds.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy